cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bio Techne Corp
1 own
9 watching
Current Price
$80.32
$0.49
(0.61%)
logo-tech
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
12,604.49M
52-Week High
52-Week High
113.805
52-Week Low
52-Week Low
68.0025
Average Volume
Average Volume
0.8M
Dividend Yield
Dividend Yield
0.002574
P/E Ratio
P/E Ratio
143.3873
iconMarket Capitalization12,604.49M
icon52-Week High113.805
icon52-Week Low68.0025
iconAverage Volume0.8M
iconDividend Yield0.002574
iconP/E Ratio143.3873
What does the Bio Techne Corp do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; polyclonal antibodies in goats, sheep, and rabbits, as well as monoclonal antibodies; microtiter-plate based kits, immunoassays based on encoded bead technology and planar spotted surfaces, and microfluidic-based immunoassays to quantify the level of a specific protein in biological fluids; and erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers fluorochrome labeled antibodies and kits to determine the immuno-phenotypic properties of cells from various tissues; and natural or synthetic chemical compounds for use as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides hematology controls and calibrators for hematology clinical instruments; clinical controls for blood glucose and blood gas devices, as well as coagulation device control products; and bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry. The Protein Platforms segment develops, manufactures, and sells tools comprising Simple Western platform, an assay for protein analysis and identification; SimplePlex platform, an assay used in research and clinical diagnostics; and Biologics Instrumentation to interrogate protein purity and identify contaminants during the development and production of biologics. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More
How much money does Bio Techne Corp make?
News & Events about Bio Techne Corp.
PR Newswire
11hours ago
BIO-TECHNE LAUNCHES THE MauriceFlex SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS BIO-TECHNE LAUNCHES THE MauriceFlex SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS PR Newswire MINNEAPOLIS, Jan. 26, 2023 MINNEAPOLIS, Jan. 26, 2023...
PR Newswire
1month ago
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire MINNEAPOLIS, Dec. 21, 2022 MINNEAPOLIS, Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck...
PR Newswire
1month ago
BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE PR Newswire MINNEAPOLIS, Nov. 28, 2022 MINNEAPOLIS, Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that...
Zolmax
3 months ago
ProShare Advisors LLC trimmed its position in shares of Bio-Techne Co. (NASDAQ:TECH Get Rating) by 28.4% in the second quarter, Holdings Channel.com reports. The firm owned 5,947 shares of the biotechnology companys stock after selling 2,357 shares during the period. ProShare Advisors LLCs holdings ...
PR Newswire
3 months ago
BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire MINNEAPOLIS, Oct. 10, 2022 MINNEAPOLIS, Oct. 10, 2022 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Bio Techne Corp share price today?
plus_minus_icon
Can Indians buy Bio Techne Corp shares?
plus_minus_icon
How can I buy Bio Techne Corp shares from India?
plus_minus_icon
Can Fractional shares of Bio Techne Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Bio Techne Corp stocks?
plus_minus_icon
What is today’s traded volume of Bio Techne Corp?
plus_minus_icon
What is today’s market capitalisation of Bio Techne Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Bio Techne Corp?
plus_minus_icon
What percentage is Bio Techne Corp down from its 52-Week High?
plus_minus_icon
What percentage is Bio Techne Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$80.32
$0.49
(0.61%)
logo-tech
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$475.91
$19.22 (4.21 %)
Meridian Bioscience Inc
Meridian Bioscience Inc
$33.97
$0.02 (0.06 %)
United Therapeutics Corporation
United Therapeutics Corporation
$264.23
$-1.69 (-0.64 %)
Emergent BioSolutions Inc
Emergent BioSolutions Inc
$13.12
$-0.34 (-2.53 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$475.91
$19.22 (4.21 %)
Meridian Bioscience Inc
Meridian Bioscience Inc
$33.97
$0.02 (0.06 %)
United Therapeutics Corporation
United Therapeutics Corporation
$264.23
$-1.69 (-0.64 %)
Emergent BioSolutions Inc
Emergent BioSolutions Inc
$13.12
$-0.34 (-2.53 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00